Critical Limb Ischemia (CLI) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Critical Limb Ischemia (CLI) Epidemiology Forecast Report Coverage

Expert Market Research's “Critical Limb Ischemia (CLI) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of critical limb ischemia (CLI). It projects the future incidence and prevalence rates of critical limb ischemia (CLI) cases across various populations. The study covers age, gender, and type as major determinants of the critical limb ischemia (CLI) population. The report highlights patterns in the prevalence of critical limb ischemia (CLI) over time and projects future trends based on multiple variables.

Critical Limb Ischemia (CLI) Understanding: Disease Overview

Critical limb ischemia, now commonly termed chronic limb-threatening ischemia (CLTI), represents the most advanced stage of peripheral artery disease. It is characterized by severely reduced blood flow to the lower extremities, leading to ischemic rest pain, non-healing ulcers, or gangrene. The condition results from progressive atherosclerotic obstruction of peripheral arteries and carries a high risk of limb loss and cardiovascular mortality. Risk factors include diabetes, smoking, hypertension, and hyperlipidemia. Early diagnosis and intervention are critical, as delayed treatment significantly increases amputation rates and mortality risk.

Critical Limb Ischemia (CLI) Epidemiology Perspective

The critical limb ischemia (CLI) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the critical limb ischemia (CLI) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for critical limb ischemia (CLI) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Peripheral artery disease, which includes CLI, affected approximately 113.7 million people globally in 2021, with an age-standardized incidence of about 115 per 100,000 person-years. CLI represents roughly 5-10% of PAD cases.
• CLI incidence rises sharply after age 60, with peak burden observed in individuals aged 70-84 years, particularly those over 75.
• While overall PAD prevalence is slightly higher in females globally, CLI and severe limb-threatening presentations are more commonly reported in males in advanced age groups.
• Higher prevalence and amputation risk have been reported among Black and South Asian populations compared to White populations, particularly in regions with elevated diabetes and cardiovascular risk factors.

Read more about this report - Request a Free Sample

Country-wise Critical Limb Ischemia (CLI) Epidemiology Segment

The critical limb ischemia (CLI) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Critical Limb Ischemia (CLI) epidemiology highlights a substantial burden across both the United States and the United Kingdom. For instance, in the United States, CLI prevalence is estimated at approximately 1.3% of the adult population, affecting nearly 2 million individuals aged 40 years and older, with an annual incidence ranging from 0.26% to 0.48%. Additionally, in the United Kingdom, chronic limb-threatening ischemia is diagnosed in roughly 500-1,000 patients per million population annually, primarily among adults aged 60 years and older. Overall, age remains a dominant risk factor shaping disease burden in both countries.

Critical Limb Ischemia (CLI): Treatment Overview

Management of chronic limb-threatening ischemia focuses on limb salvage and cardiovascular risk reduction. Revascularization remains the cornerstone of therapy and may be achieved through endovascular interventions such as angioplasty and stenting or surgical bypass procedures. Adjunctive wound care and infection control are essential to prevent tissue loss. Pharmacologic management includes antiplatelet agents, statins, and glycemic control in diabetic patients. In severe, non-reconstructable cases, amputation may be required. Ongoing innovations in drug-coated devices and regenerative therapies aim to improve long-term limb preservation outcomes.

Key Questions Answered

• What are the key findings of critical limb ischemia (CLI) epidemiology in the 8 major markets?
• What will be the total number of patients with critical limb ischemia (CLI) across the 8 major markets during the forecast period?
• What was the country-wise critical limb ischemia (CLI) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of critical limb ischemia (CLI) patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of critical limb ischemia (CLI) during the forecast period of 2026-2035?
• What are the currently available treatments for critical limb ischemia (CLI)?
• What are the disease risks, signs, symptoms, and unmet needs of critical limb ischemia (CLI)?

Scope of the Critical Limb Ischemia (CLI) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of critical limb ischemia (CLI) based on several factors.
• Critical Limb Ischemia (CLI) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The critical limb ischemia (CLI) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Critical Limb Ischemia Pipeline Analysis

Ischemia Reperfusion Injury Therapeutics Market